The UK government has unveiled a £400 million ($530 million) investment program aimed at enhancing clinical trials and accelerating access to new treatments through the country’s national healthcare provider.
The public-private collaboration will establish 18 new clinical trials hubs across the UK, designed to streamline research processes and bring cutting-edge therapies to patients more quickly.
Health Secretary Wes Streeting emphasized that this investment will “fast-track the next generation of treatments to NHS patients” and position the UK as a “global leader” in health research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze